RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression
|
|
|
|
|
|
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD
|
|
|
|
|
|